Ovid Therapeutics Inc.
OVIDNasdaq
$2.44
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +525.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$7.1M
Net Income (TTM)
-$24.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-670.3%
Net Margin
-339.1%
ROE
-12.2%
ROIC
-88.2%
Debt / Equity
—
Net Cash
$155.5M
Return 1Y
+409.1%
Company profile
Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.
- CEO
- Jeremy M. Levin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- New York
- Website
- ovidrx.com
Management & directors
- Carter Charles RossChief Financial Officer
- Levin Jeremy MExecutive Chairman
- Rona Jeffrey ACBFO
- Alexander Margaret A.President and CEO
Roles derived from SEC Form 4 filings.
Earnings
OVID Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $208.4M | $1.5M | $392,000.00 | $566,000.00 | $7.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$81.4M | $124.2M | -$55.5M | -$59.3M | -$61.9M | -$42.4M |
| Net income | -$81.0M | $122.8M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Diluted EPS | -$1.39 | $1.76 | -$0.77 | -$0.74 | — | — |
| Operating cash flow | -$51.6M | $118.6M | -$55.2M | -$45.8M | -$56.0M | -$38.3M |
| Free cash flow | -$51.7M | $118.4M | -$56.5M | -$45.8M | -$56.0M | -$38.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -645.4% | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Net margin | -642.3% | 58.9% | -3604.7% | -13341.8% | -4664.3% | -239.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $169,000.00 | $173,000.00 | $76,000.00 | $130,000.00 | $6.3M | $132,000.00 | $718,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$20.5M | -$13.2M | -$10.7M | -$12.6M | -$5.1M | -$12.5M | -$12.3M | -$17.8M |
| Net income | $8.5M | -$14.0M | -$9.2M | -$10.2M | -$4.7M | -$12.2M | $9.7M | -$17.0M |
| Diluted EPS | $0.12 | -$0.20 | — | — | — | — | — | — |
| Operating cash flow | -$14.3M | -$15.0M | -$10.0M | -$10.3M | -$4.8M | -$12.9M | -$10.4M | -$13.9M |
| Free cash flow | -$14.3M | -$15.0M | -$10.0M | -$10.3M | -$4.8M | -$12.9M | -$10.4M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -12140.2% | -7645.1% | -14111.8% | -9653.8% | -80.9% | -9487.1% | -1712.1% | — |
| Net margin | 5042.0% | -8096.0% | -12132.9% | -7873.1% | -74.7% | -9210.6% | 1347.8% | — |
Company news
Jul 14, 2026
Jun 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Carter Charles Ross· Chief Financial Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-04-07 | PAPADOPOULOS STELIOS | Award | 17,578 | $2.56 | $44,999.68 | filing |
| 2026-04-07 | Fitzgerald Kevin Joseph | Award | 17,578 | $2.56 | $44,999.68 | filing |
| 2026-04-07 | Friedman Bart | Award | 8,789 | $2.56 | $22,499.84 | filing |
| 2026-03-23 | LEVIN JEREMY M· Executive Chairman | Option exercise | 47,333 | $1.40 | $66,266.20 | filing |
| 2026-02-26 | Rona Jeffrey A· CBFO | Award | 68,125 | $0.00 | $0.00 | filing |
| 2026-02-23 | ALEXANDER MARGARET A.· President and CEO | Sale | 11,656 | $1.45 | $16,901.20 | filing |
| 2026-02-23 | Rona Jeffrey A· CBFO | Sale | 8,541 | $1.45 | $12,384.45 | filing |
| 2025-12-15 | LEVIN JEREMY M· CEO | C | 71,000 | — | — | filing |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO LTD | C | 1,250,000 | $0.00 | $0.00 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.